Roth Capital Maintains Buy on Nuvectis Pharma, Raises Price Target to $33

Roth Capital analyst Jonathan Aschoff maintains Nuvectis Pharma (NASDAQ:NVCT) with a Buy and raises the price target from $20 to $33.